SG11201400897UA - Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactives - Google Patents

Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactives

Info

Publication number
SG11201400897UA
SG11201400897UA SG11201400897UA SG11201400897UA SG11201400897UA SG 11201400897U A SG11201400897U A SG 11201400897UA SG 11201400897U A SG11201400897U A SG 11201400897UA SG 11201400897U A SG11201400897U A SG 11201400897UA SG 11201400897U A SG11201400897U A SG 11201400897UA
Authority
SG
Singapore
Prior art keywords
phenylephrine
oral bioavailability
increasing oral
metabolic approach
selective metabolic
Prior art date
Application number
SG11201400897UA
Inventor
Phillip M Gerk
William H Barr
Joseph K Ritter
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Publication of SG11201400897UA publication Critical patent/SG11201400897UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
SG11201400897UA 2011-09-27 2012-09-27 Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactives SG11201400897UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539530P 2011-09-27 2011-09-27
US201161544396P 2011-10-07 2011-10-07
PCT/US2012/057588 WO2013049365A2 (en) 2011-09-27 2012-09-27 Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactives

Publications (1)

Publication Number Publication Date
SG11201400897UA true SG11201400897UA (en) 2014-04-28

Family

ID=47996740

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201400897UA SG11201400897UA (en) 2011-09-27 2012-09-27 Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactives

Country Status (15)

Country Link
US (1) US9616033B2 (en)
EP (1) EP2760441A2 (en)
JP (1) JP2014527999A (en)
KR (1) KR20140097135A (en)
AU (1) AU2012316001A1 (en)
BR (1) BR112014007376A2 (en)
CA (1) CA2849473A1 (en)
CL (1) CL2014000747A1 (en)
CO (1) CO6970592A2 (en)
IL (1) IL231635A0 (en)
MX (1) MX2014003606A (en)
PE (1) PE20142043A1 (en)
RU (1) RU2014116639A (en)
SG (1) SG11201400897UA (en)
WO (1) WO2013049365A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015025684A2 (en) * 2013-04-08 2017-07-18 Indivior Uk Ltd method for providing one or more opioid (s) to an individual, dosage form, method for treating or preventing pain and method for treating or preventing addiction or addiction
ES2829644T3 (en) 2014-06-20 2021-06-01 Hermes Arzneimittel Gmbh Flavor Masked Oral Pharmaceutical Composition
JP6706245B2 (en) * 2014-07-30 2020-06-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Directly compressible composition containing microcrystalline cellulose
KR101621426B1 (en) 2014-08-20 2016-05-16 선문대학교 산학협력단 Novel Alpha-Mangostin Glycosides Derivates and Method for Preparing the Same
FR3027228B1 (en) * 2014-10-20 2016-12-09 Valbiotis COMPOSITION COMPRISING A MIXTURE OF PLANT EXTRACTS AND USE FOR ACTING ON GLUCIDIC AND / OR LIPID METABOLISM
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US20160106721A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
CN107515307A (en) * 2017-10-13 2017-12-26 基蛋生物科技股份有限公司 A kind of immune cardiovascular eight Indexs measure test strips of dry type
WO2020049588A1 (en) * 2018-09-05 2020-03-12 THAKKAR Hetal Paresh Technology for enhancing bioavalaibility of selective estrogen receptor modulator (serm)
CN113671093A (en) * 2020-05-13 2021-11-19 上海大学 Method for rapidly detecting p-hydroxybenzoic acid substances in human urine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493827A (en) 1983-11-14 1985-01-15 Ronald Valle Method of inducing sleep
WO1994025009A1 (en) * 1993-04-30 1994-11-10 The Procter & Gamble Company Coated pharmaceutical compositions
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US6759062B2 (en) 2000-02-23 2004-07-06 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
JP2004509920A (en) 2000-09-29 2004-04-02 ボード　オブ　トラスティーズ　オペレーティング　ミシガン　ステート　ユニヴァーシティ Catecholamine pharmaceutical compositions and methods
WO2003055494A1 (en) 2001-12-21 2003-07-10 Avmax, Inc. Use of ugt inhibitors to increase bioavailability
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20070160688A1 (en) * 2006-01-10 2007-07-12 Eric Marchewitz Use of flavonoids to increase blood serum levels of dehydroepiandrosterone
US20070160689A1 (en) 2006-01-12 2007-07-12 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
JP5175278B2 (en) * 2006-06-01 2013-04-03 エムエスディー コンシューマー ケア， インコーポレイテッド Phenylephrine pharmaceutical formulations and compositions for colonic absorption
WO2008033155A1 (en) 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
AU2009249069A1 (en) * 2008-05-20 2009-11-26 Neurogesx, Inc. Carbonate prodrugs and methods of using the same

Also Published As

Publication number Publication date
US20140221426A1 (en) 2014-08-07
BR112014007376A2 (en) 2017-04-04
CA2849473A1 (en) 2013-04-04
MX2014003606A (en) 2015-01-16
AU2012316001A1 (en) 2014-04-10
CL2014000747A1 (en) 2015-02-27
IL231635A0 (en) 2014-05-28
EP2760441A2 (en) 2014-08-06
KR20140097135A (en) 2014-08-06
US9616033B2 (en) 2017-04-11
WO2013049365A2 (en) 2013-04-04
RU2014116639A (en) 2015-11-10
CO6970592A2 (en) 2014-06-13
WO2013049365A3 (en) 2013-05-30
JP2014527999A (en) 2014-10-23
PE20142043A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
SG11201400897UA (en) Selective metabolic approach to increasing oral bioavailability of phenylephrine and other phenolic bioactives
HK1245110B (en) Solid forms of isoquinolinones
HRP20190576T1 (en) Methods of preparation of conjugates
ZA201306237B (en) Solid forms of a pharmaceutically active substance
EP2672820A4 (en) Mannoside compounds and methods of use thereof
TWI563816B (en) Backwards-compatible approach to fields of a protocol layer
GB201110850D0 (en) Catalyst and mehtod of preparation
EP2772483A4 (en) 4-aminocarbazole compound and use of same
IL229463A0 (en) Rapid detection of metabolic activity
EP2548859A4 (en) Preparation methods of methyl-d3-amine and salts thereof
HK1194964A1 (en) Parenteral administration of tapentadol
HK1192323A1 (en) Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles glu-
HK1189056A1 (en) Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles bubr1
HK1185947A1 (en) Use of stathmin as a biomarker of drug response to furazanobenzimidazoles stathmin
EP2771805A4 (en) Throttling of rogue entities to push notification servers
BR112014015885A2 (en) pharmaceutical preparation
IL229742A0 (en) Hyperforin analogs,methods of synthesis,and uses thereof
EP2684869A4 (en) Preparation of 3-mercaptopropionates
SG11201400977QA (en) Pharmaceutical methods and topical compositions containing acitretin
PL395425A1 (en) Preparation of 2-amino-N-tert-butyl-2-cyanoacetamide hydrochloride
FR2970496B1 (en) STRUCTURE AS OFFICE OF MARQUISE
HUP1100272A2 (en) Pharmaceutical use of silicic acid
TH120186B (en) Pedaling devices and methods of making pedaling devices
TWM432265U (en) Improved structure of connection member
GB201112082D0 (en) Prodrugs of pharmaceologically active phenolic drug metabolites and uses thereof